Trial Profile
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary) ; Allopurinol
- Indications Gout
- Focus Adverse reactions; Registrational
- Acronyms CARES
- Sponsors Takeda
- 15 Nov 2023 Results (n= 6183) of post-hoc Cohort Analysis of CARES with Consideration of Drop-out, presented at the ACR Convergence 2023.
- 04 Jun 2022 Results (n=4144) of a study assessing impact of urate-lowering therapy on progression of Chronic kidney disease in gout patients by analyzing changes in estimated glomerular filtration rate slope using data from this trial presented at the 23rd Annual Congress of the European League Against Rheumatism
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting